Pyxis Oncology (PYXS) Assets Average (2021 - 2026)
Pyxis Oncology (PYXS) posted quarterly Assets Average of $98.6 million for Q4 2025, down 44.08% year-over-year from $176.2 million in Q4 2024, and down 13.85% quarter-over-quarter from $114.4 million in Q3 2025.
Pyxis Oncology (PYXS) Assets Average (2021 - 2026) Analysis & Trends
Pyxis Oncology (PYXS) has reported Assets Average for 5 consecutive years, with $98.6 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Assets Average fell 44.08% year-over-year to $98.6 million; the TTM figure through Dec 2025 stood at $98.6 million (down 44.08% YoY), while the FY2025 annual figure was $124.4 million, down 24.84% from the prior year.
- Assets Average eased to $98.6 million in Q4 2025 per PYXS's latest filing, from $114.4 million in the prior quarter.
- Across five years, Assets Average topped out at $266.4 million in Q1 2022 and bottomed at $98.6 million in Q4 2025.
- Historically, Assets Average has averaged $187.7 million across 5 years, with a median of $197.0 million in 2024.
- Annual changes were most pronounced in 2024 — Assets Average rose 19.71% — and 2025, when it sank 44.08%.
- Pyxis Oncology's Assets Average stood at $209.8 million in 2021, then advanced by 3.76% to $217.6 million in 2022, then slipped by 17.2% to $180.2 million in 2023, then fell by 2.2% to $176.2 million in 2024, then tumbled by 44.08% to $98.6 million in 2025.
- Business Quant data shows PYXS's Assets Average at $98.6 million in Q4 2025, $114.4 million in Q3 2025, and $129.5 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 5.34 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 2.09 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.82 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 25.27 Bn |
| 10 | Pyxis Oncology | 199.01 Mn | 166.02 Mn | - | 73.22 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 73.22 Mn |
| Dec 31, 2025 | 98.56 Mn |
| Sep 30, 2025 | 114.41 Mn |
| Jun 30, 2025 | 129.54 Mn |
| Mar 31, 2025 | 146.52 Mn |
| Dec 31, 2024 | 176.25 Mn |
| Sep 30, 2024 | 201.85 Mn |
| Jun 30, 2024 | 214.30 Mn |
| Mar 31, 2024 | 196.97 Mn |
| Dec 31, 2023 | 180.21 Mn |
| Sep 30, 2023 | 180.96 Mn |
| Jun 30, 2023 | 179.02 Mn |
| Mar 31, 2023 | 197.09 Mn |
| Dec 31, 2022 | 217.64 Mn |
| Sep 30, 2022 | 233.23 Mn |
| Jun 30, 2022 | 247.63 Mn |
| Mar 31, 2022 | 266.36 Mn |
| Dec 31, 2021 | 209.75 Mn |